SE9703377D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9703377D0
SE9703377D0 SE9703377A SE9703377A SE9703377D0 SE 9703377 D0 SE9703377 D0 SE 9703377D0 SE 9703377 A SE9703377 A SE 9703377A SE 9703377 A SE9703377 A SE 9703377A SE 9703377 D0 SE9703377 D0 SE 9703377D0
Authority
SE
Sweden
Prior art keywords
alkyl
enantiomers
cycloalkyl
aryl
active compounds
Prior art date
Application number
SE9703377A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Martin Nyloef
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703377A priority Critical patent/SE9703377D0/xx
Publication of SE9703377D0 publication Critical patent/SE9703377D0/xx
Priority to ZA987813A priority patent/ZA987813B/xx
Priority to HU0100684A priority patent/HUP0100684A3/hu
Priority to HR20000132A priority patent/HRP20000132A2/hr
Priority to JP2000511761A priority patent/JP4150161B2/ja
Priority to PL98339664A priority patent/PL339664A1/xx
Priority to AT98944377T priority patent/ATE255098T1/de
Priority to EP98944377A priority patent/EP1025095B1/fr
Priority to US09/171,570 priority patent/US6479497B1/en
Priority to BR9812238-0A priority patent/BR9812238A/pt
Priority to KR1020007002823A priority patent/KR20010024077A/ko
Priority to IL13507398A priority patent/IL135073A0/xx
Priority to AU91932/98A priority patent/AU734580B2/en
Priority to SK286-2000A priority patent/SK2862000A3/sk
Priority to DE69820102T priority patent/DE69820102T2/de
Priority to CN98811112A priority patent/CN1278810A/zh
Priority to EEP200000140A priority patent/EE200000140A/xx
Priority to PCT/SE1998/001603 priority patent/WO1999014212A1/fr
Priority to CA002304037A priority patent/CA2304037A1/fr
Priority to TR2000/00736T priority patent/TR200000736T2/xx
Priority to ARP980104636A priority patent/AR015449A1/es
Priority to IS5402A priority patent/IS5402A/is
Priority to NO20001402A priority patent/NO20001402L/no
Priority to US10/285,743 priority patent/US6670359B2/en
Priority to US10/714,577 priority patent/US7056921B2/en
Priority to US11/447,589 priority patent/US7384943B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE9703377A 1997-09-18 1997-09-18 New compounds SE9703377D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE9703377A SE9703377D0 (sv) 1997-09-18 1997-09-18 New compounds
ZA987813A ZA987813B (en) 1997-09-18 1998-08-27 Substituted chroman derivatives
TR2000/00736T TR200000736T2 (tr) 1997-09-18 1998-09-09 İkame edilmiş kroman türevleri.
AU91932/98A AU734580B2 (en) 1997-09-18 1998-09-09 Substituted chroman derivatives
SK286-2000A SK2862000A3 (en) 1997-09-18 1998-09-09 Substituted chroman derivatives
JP2000511761A JP4150161B2 (ja) 1997-09-18 1998-09-09 置換されたクロマン誘導体
PL98339664A PL339664A1 (en) 1997-09-18 1998-09-09 Substituted derivatives of chromane
AT98944377T ATE255098T1 (de) 1997-09-18 1998-09-09 Substituierte chromanderivate
EP98944377A EP1025095B1 (fr) 1997-09-18 1998-09-09 Derives de chromane substitues
US09/171,570 US6479497B1 (en) 1997-09-18 1998-09-09 Substituted chroman derivatives
BR9812238-0A BR9812238A (pt) 1997-09-18 1998-09-09 Composto, uso deste, processo para a preparação do mesmo, formulação farmacêutica, e, processos para o tratamento de distúrbios do sistema nervoso central e/ou incontinência urinária, ou vasoespasmo, ou para controle de crescimento de tumores, e para o tratamento de distúrbios mediados por 5-hidroxitriptamina
KR1020007002823A KR20010024077A (ko) 1997-09-18 1998-09-09 치환된 크로만 유도체
IL13507398A IL135073A0 (en) 1997-09-18 1998-09-09 Substituted chroman derivatives
HU0100684A HUP0100684A3 (en) 1997-09-18 1998-09-09 Substituted chroman derivatives, process for their preparation and medicaments containing them
HR20000132A HRP20000132A2 (en) 1997-09-18 1998-09-09 Substituted chroman derivatives
DE69820102T DE69820102T2 (de) 1997-09-18 1998-09-09 Substituierte chromanderivate
CN98811112A CN1278810A (zh) 1997-09-18 1998-09-09 取代的苯并二氢吡喃衍生物
EEP200000140A EE200000140A (et) 1997-09-18 1998-09-09 Asendatud kromaani derivaadid
PCT/SE1998/001603 WO1999014212A1 (fr) 1997-09-18 1998-09-09 Derives de chromane substitues
CA002304037A CA2304037A1 (fr) 1997-09-18 1998-09-09 Derives de chromane substitues
ARP980104636A AR015449A1 (es) 1997-09-18 1998-09-17 Derivados piperidil- o peperazinil-dihidro sustituidos-2h-1-benzopirano composicion farmaceutica que los contiene, su uso para la elaboracion de unmedicamento, procedimiento para su preparacion y compuesto intermediario para su exclusivo uso en dicho procedimiento
IS5402A IS5402A (is) 1997-09-18 2000-03-14 Útskiptar króman afleiður
NO20001402A NO20001402L (no) 1997-09-18 2000-03-17 Substituerte kromanderivater
US10/285,743 US6670359B2 (en) 1997-09-18 2002-11-01 Substituted chroman derivatives
US10/714,577 US7056921B2 (en) 1997-09-18 2003-11-13 Substituted chroman derivatives
US11/447,589 US7384943B2 (en) 1997-09-18 2006-06-05 Substituted chroman derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703377A SE9703377D0 (sv) 1997-09-18 1997-09-18 New compounds

Publications (1)

Publication Number Publication Date
SE9703377D0 true SE9703377D0 (sv) 1997-09-18

Family

ID=20408297

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703377A SE9703377D0 (sv) 1997-09-18 1997-09-18 New compounds

Country Status (23)

Country Link
US (4) US6479497B1 (fr)
EP (1) EP1025095B1 (fr)
JP (1) JP4150161B2 (fr)
KR (1) KR20010024077A (fr)
CN (1) CN1278810A (fr)
AR (1) AR015449A1 (fr)
AT (1) ATE255098T1 (fr)
AU (1) AU734580B2 (fr)
BR (1) BR9812238A (fr)
CA (1) CA2304037A1 (fr)
DE (1) DE69820102T2 (fr)
EE (1) EE200000140A (fr)
HR (1) HRP20000132A2 (fr)
HU (1) HUP0100684A3 (fr)
IL (1) IL135073A0 (fr)
IS (1) IS5402A (fr)
NO (1) NO20001402L (fr)
PL (1) PL339664A1 (fr)
SE (1) SE9703377D0 (fr)
SK (1) SK2862000A3 (fr)
TR (1) TR200000736T2 (fr)
WO (1) WO1999014212A1 (fr)
ZA (1) ZA987813B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
WO2002020500A2 (fr) * 2000-09-01 2002-03-14 Icos Corporation Substances potentialisant un traitement anticancereux et methodes a cet effet
NZ535574A (en) 2001-01-16 2006-07-28 Astrazeneca Ab Therapeutic heterocyclic compounds
MXPA03006268A (es) 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos terapeuticos de cromano.
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (fr) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Derives de chromane
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP2316458A1 (fr) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Derives de pyridazine destines a l'inhibition du desaturase-coa-stearoyl de l'humain
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1804799B1 (fr) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
CA2580856A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
EP1799667B1 (fr) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
EP2289510A1 (fr) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
EP2029138A1 (fr) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
WO2008130323A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 8-pipérazine-tétrahydronaphtalène utilisés pour le traitement de la douleur
WO2008130321A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 807
WO2008130319A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 805
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
WO2008130322A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 5-hétérocyclyl-chromane utilisés pour le traitement de la douleur
TWI402072B (zh) 2010-10-19 2013-07-21 Lilly Co Eli 組織蛋白酶ｓ抑制劑化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE56007T1 (de) * 1984-06-22 1990-09-15 Beecham Group Plc Wirksame benzopyranverbindungen.
IT1190405B (it) * 1985-10-22 1988-02-16 Recordati Chem Pharm Derivati del flavone
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
AU627027B2 (en) 1989-04-27 1992-08-13 Pharmacia & Upjohn Company Substituted 3-amino chromans
US5420151A (en) 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
WO1997007120A1 (fr) * 1995-08-11 1997-02-27 Smithkline Beecham Plc Derives de biphenyl(thio)amide et de biphenylethan(thi)one, leur preparation et leur utilisation comme antagonistes des recepteurs 5-ht¿1d?
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
UY29896A1 (es) * 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY29892A1 (es) * 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones

Also Published As

Publication number Publication date
EP1025095B1 (fr) 2003-11-26
US6670359B2 (en) 2003-12-30
PL339664A1 (en) 2001-01-02
TR200000736T2 (tr) 2000-07-21
US7056921B2 (en) 2006-06-06
ZA987813B (en) 1999-03-18
SK2862000A3 (en) 2000-11-07
CA2304037A1 (fr) 1999-03-25
CN1278810A (zh) 2001-01-03
DE69820102D1 (de) 2004-01-08
NO20001402L (no) 2000-05-09
WO1999014212A1 (fr) 1999-03-25
EE200000140A (et) 2001-02-15
IS5402A (is) 2000-03-14
NO20001402D0 (no) 2000-03-17
HUP0100684A2 (hu) 2002-05-29
IL135073A0 (en) 2001-05-20
US20030100556A1 (en) 2003-05-29
US7384943B2 (en) 2008-06-10
US20060223828A1 (en) 2006-10-05
HRP20000132A2 (en) 2001-12-31
HUP0100684A3 (en) 2002-06-28
EP1025095A1 (fr) 2000-08-09
AR015449A1 (es) 2001-05-02
BR9812238A (pt) 2000-07-18
JP2001516754A (ja) 2001-10-02
DE69820102T2 (de) 2004-07-15
ATE255098T1 (de) 2003-12-15
KR20010024077A (ko) 2001-03-26
US20040157857A1 (en) 2004-08-12
US6479497B1 (en) 2002-11-12
JP4150161B2 (ja) 2008-09-17
AU734580B2 (en) 2001-06-14
AU9193298A (en) 1999-04-05

Similar Documents

Publication Publication Date Title
YU2300A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
NO20001402L (no) Substituerte kromanderivater
CA2011346A1 (fr) Derives de 2-(1-piperazinyl)-4-phenylcycloalkanopyridine, procede de production, et compose pharmaceutique les contenant
YU40998A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
PE20010482A1 (es) Derivados de 3-ureido-pirazol y procedimiento para su preparacion
SE9703378D0 (sv) New compounds
SE0101579D0 (sv) New compounds
WO2001046144A8 (fr) Nouveaux modulateurs de la neurotransmission de dopamine
MXPA03010584A (es) Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas.
CA2284795A1 (fr) Nouveaux derives de pyrimidine et procedes de preparation desdits derives
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
AR041246A1 (es) Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene
KR890001957A (ko) N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용
DE60105610D1 (en) Pyrazinonderivate
ATE153666T1 (de) Phosphono-arylethanolamin-verbindungen mit antihyperglykämischer und/oder antiobeser wirkung
HUT59124A (en) Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
PT86677A (pt) Process for the preparation of cinnoline-carboxamides and of pharmaceutical compositions containing the same
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PT1161424E (pt) Novos derivados de diazole como agentes serotonergicos
IE820160L (en) Heterocyclic benzamide derivatives
YU28701A (sh) N-(2-(heteroaril)etil)-3-fenilpiperidini, n-(2-(heteroaril) etil)-4-fenilpiperidin i srodna jedinjenja sa supstituentom u položaju 4 piperidinskog prstena
DK0850939T3 (da) Ellipticin-derivater, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende derivaterne
ECSP003642A (es) Antagonistas muscarinicos
TH67350A (th) อนุพันธ์เอซิลอะมิโนไทอะโซล, การเตรียมสารดังกล่าวและการใช้ทางการบำบัด